BI 655066 / ABBV-066 / risankizumab compared to placebo in patients with active psoriatic arthritis

Registry ID

EUCTR2015-003625-34

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Boehringer Ingelheim Finland Ky

Start date

2016-02-16

Completion date

2017-08-24

Last update

2026-08-16

Conditions

• Active Psoriatic Arthritis

Summary

Primary objective is to compare efficacy of BI 655066 versus placebo at week 16, based on ACR 20 response.

Locations

• , , Netherlands
• , , Germany
• , , Finland
• , , Belgium
• , , Spain
• , , Czechia
• , , France

Related clinical trials

• Korean Post-marketing Surveillance for Xeljanz XR

View on source registry